Narcolepsy Following Pandemrix Influenza Vaccination in Europe
An increased risk of narcolepsy was found following vaccination with Pandemrix, a monovalent 2009 H1N1 influenza vaccine that was used in several European countries during the H1N1 influenza pandemic. Narcolepsy is a chronic neurological disorder caused by the brain’s inability to regulate sleep-wake cycles normally. This risk was initially found in Finland, and then some other European countries also detected an association. Most recently, scientists at the United Kingdom’s (UK) Health Protection Agency (HPA) have found evidence of an association between Pandemrix and narcolepsy in children in England. The findings are consistent with studies from Finland and other countries.
Pandemrix is manufactured by GlaxoSmithKline in Europe and was specifically produced for pandemic 2009 H1N1 influenza. It was not used before 2009, and has not been used since the influenza pandemic season (2009-2010). It contains an oil-in-water emulsion adjuvant called ASO3. Adjuvants are substances added to a vaccine to increase the body’s immune response to that vaccine.
Pandemrix was not licensed for use in the United States.
In response to the events in Europe, CDC reviewed data from the U.S. Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) and found no indication of any association between U.S.-licensed H1N1 or seasonal influenza vaccine and narcolepsy.
In 2014, CDC published a studyExternal on the association between 2009 H1N1 influenza vaccines, 2010/2011 seasonal influenza vaccines, and narcolepsy. The analysis included more than 650,000 people who received the pandemic flu vaccine in 2009 and over 870,000 people who received the seasonal flu vaccine in 2010/2011. The study found that vaccination was not associated with an increased risk for narcolepsy.
CDC recommends influenza vaccination as the best way to protect from influenza disease and its complications. See CDC influenza vaccine recommendations.
Related Scientific Articles
Duffy J, Weintraub E, Vellozzi C, DeStefano F; Vaccine Safety Datalink. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United StatesExternal. Neurology. 2014 Nov 11;83(20):1823-30.
European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation)Cdc-pdfExternal. Stockholm: ECDC; September 2012.
Eurosurveillance editorial team. Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexyExternal. Euro Surveill. 2011;16(26).
Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al. Risk of narcolepsy in children receiving an AS03 adjuvanted AH1N1 (2009) influenza vaccine in EnglandExternal. BMJ. 2013;346:f794
Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in FinlandExternal. PLoS One. 2012;7(3):e33536.
Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, Hublin C, Linna M, Olsén P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in FinlandExternal. PLoS One. 2012;7(3):e33723.